Andrew Newland founded ANGLE PLC (AIM:AGL) in 1994. Twenty-eight years on and his company has won FDA clearance for ANGLE’s liquid biopsy Parsortix initiative which in the U.S. alone has a $100 billion per annum addressable market.

“We’re solving an enormously challenging and important medical question,” says Newland who says the ultimate growth of Parsortix is unbounded.